Zeidner, Joshua F. http://orcid.org/0000-0002-9014-1514
Lin, Tara L.
Vigil, Carlos E.
Fine, Gil
Yair Levy, M.
Nazha, Aziz
Esteve, Jordi http://orcid.org/0000-0002-8056-648X
Lee, Daniel J.
Yee, Karen
Dalovisio, Andrew
Wang, Eunice S.
Bergua Burgues, Juan M.
Schriber, Jeffrey
Litzow, Mark R. http://orcid.org/0000-0002-9816-6302
Frankfurt, Olga
Castillo, Teresa Bernal Del
Bhatt, Vijaya Raj http://orcid.org/0000-0003-2513-0533
Bhatnagar, Bhavana
Mehta, Priyanka
Dillon, Richard
Vicente, Maria Vidriales http://orcid.org/0000-0001-5049-3673
Anthony, Stephen
Bearss, David
Montesinos, Pau http://orcid.org/0000-0002-3275-5593
Douglas Smith, B.
Funding for this research was provided by:
Sumitomo Dainippon Pharma Oncology, Lehi, UT
Article History
Received: 17 August 2021
Revised: 18 October 2021
Accepted: 19 October 2021
First Online: 30 October 2021
Competing interests
: J.F.Z. has served as a consultant for AbbVie and Takeda; received honoraria from advisory boards from Agios/Servier, Bristol Myers Squibb/Celgene, Genentech, Gilead, Shattuck Labs, and Takeda and has received research funding from Arog, Astex, Gilead/Forty Seven, Merck, Sumitomo Dainippon Pharma/Tolero, Takeda. G.F., S.A., and D.B. were employed by Sumitomo Dainippon Pharma. D.J.L. received consulting fees from Celgene and research funding (institutional) from AbbVie, Bayer, Genentech, Gilead/Forty Seven, Novartis, and Tolero. At the time of publication, D.J.L. will be employed by Cellectis. K.Y. consulted for and/or received honorarium from Novartis, F. Hoffmann La Roche, Shattuck Labs, Takeda, Pfizer, TaiHo, Bristol-Myers Squib/Celgene, Paladin, Astex, and Otsuka and has received research funding from Astex, Novartis, Forma Therapeutics, Jazz, Onconova, F. Hoffmann La Roche, Genentech, and Tolero. E.S.W. has received honoraria from advisory boards from AbbVie, Astellas, BMS/Celgene, Genentech, GlaxoSmithKline, Jazz, Kite Pharmaceuticals, Kura Oncology, Novartis, Pfizer, Stemline, and Takeda; consultancy from Mana Therapeutics; speaker role for Stemline, Kura, Pfizer, and Dava Oncology; and has served on data monitoring committees with AbbVie and Rafael Pharmaceuticals. M.R.L. has served on advisory boards from Omeros and Jazz; has served on Data Monitoring Committee with Biosight; and receives research funding from AbbVie, Astellas, Amgen, Actinium, and Pluristem. P.M. has received advisory board honoraria from Pfizer, Jazz Pharmaceuticals, AbbVie, Celgene, Daichii Sankyo, and Takeda and educational grant from Jazz Pharmaceuticals, Daichii Sankyo, Novartis, and Celgene. R.D. has received honoraria from advisory boards from AbbVie, Jazz, Menarini, Novartis, and Pfizer; consultancy from AbbVie, Astellas, Jazz, Novartis, and Pfizer; and research funding from AbbVie and Amgen. V.R.B. is receiving consulting fees from Genentech, Rigel, Agios, Incyte, Omeros, Takeda, Partnership for health analytic research, LLC (which, in turn, receives funds from Jazz Pharmaceuticals), and AbbVie, research funding (institutional) from AbbVie, Pfizer, Incyte, Jazz, Tolero Pharmaceuticals, Inc., and National Marrow Donor Program; drug support (institutional) from Oncoceutics for a trial; and educational grant (institutional) from Pfizer and Novartis. B.D.S. has served as a consultant for Bristol Myers Squibb/Celgene, Jubilant, Novartis, and Pfizer and has served on DSMB for Bristol Myers Squibb/Celgene and Cellularity. All other authors declare no competing interests or disclosures.